HC Wainwright Has Pessimistic Outlook of ETON Q2 Earnings

Eton Pharmaceuticals, Inc. (NASDAQ:ETON) – Equities research analysts at HC Wainwright cut their Q2 2026 earnings per share (EPS) estimates for Eton Pharmaceuticals in a research report issued to clients and investors on Tuesday, August 11th. HC Wainwright analyst S. Ramakanth now forecasts that the company will post earnings per share of $0.11 for the quarter, down from their previous estimate of $0.15. HC Wainwright has a “Buy” rating and a $65.00 price objective on the stock. The consensus estimate for Eton Pharmaceuticals’ current full-year earnings is $0.75 per share. HC Wainwright also issued estimates for Eton Pharmaceuticals’ Q3 2026 earnings at $0.17 EPS, Q4 2026 earnings at $0.19 EPS, FY2026 earnings at $0.52 EPS, Q1 2027 earnings at $0.26 EPS, Q2 2027 earnings at $0.30 EPS, Q3 2027 earnings at $0.36 EPS and Q4 2027 earnings at $0.35 EPS.

A number of other research analysts have also issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research note on Friday, July 17th. Wall Street Zen upgraded shares of Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 13th. Craig Hallum boosted their price objective on shares of Eton Pharmaceuticals from $40.00 to $62.00 and gave the company a “buy” rating in a report on Tuesday, July 28th. Canaccord Genuity Group initiated coverage on Eton Pharmaceuticals in a research report on Thursday, July 16th. They issued a “buy” rating and a $60.00 target price on the stock. Finally, Zacks Research cut Eton Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research report on Monday, July 13th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Eton Pharmaceuticals has an average rating of “Moderate Buy” and an average price target of $54.50.

Eton Pharmaceuticals Stock Down 3.7%

ETON stock opened at $42.05 on Wednesday. The firm has a 50 day moving average of $37.95 and a 200 day moving average of $28.01. The stock has a market capitalization of $1.15 billion, a PE ratio of -600.63 and a beta of 0.86. The company has a quick ratio of 0.88, a current ratio of 1.21 and a debt-to-equity ratio of 0.62. Eton Pharmaceuticals has a 52 week low of $14.27 and a 52 week high of $50.18.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Thursday, May 14th. The company reported $0.05 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.05). Eton Pharmaceuticals had a negative return on equity of 5.68% and a negative net margin of 1.70%.The business had revenue of $24.27 million for the quarter, compared to analysts’ expectations of $22.31 million.

Institutional Investors Weigh In On Eton Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Quarry LP acquired a new stake in Eton Pharmaceuticals during the 3rd quarter worth about $37,000. Legal & General Group Plc purchased a new stake in shares of Eton Pharmaceuticals in the second quarter worth about $41,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Eton Pharmaceuticals in the fourth quarter worth about $44,000. China Universal Asset Management Co. Ltd. acquired a new stake in Eton Pharmaceuticals during the fourth quarter worth about $74,000. Finally, Persistent Asset Partners Ltd purchased a new position in Eton Pharmaceuticals during the second quarter valued at approximately $90,000. 27.86% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Eton Pharmaceuticals

In other Eton Pharmaceuticals news, insider David Krempa sold 19,679 shares of Eton Pharmaceuticals stock in a transaction that occurred on Wednesday, May 27th. The shares were sold at an average price of $31.47, for a total transaction of $619,298.13. Following the completion of the sale, the insider directly owned 25,249 shares in the company, valued at approximately $794,586.03. The trade was a 43.80% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Jennifer Mckie Adams sold 50,000 shares of the company’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total transaction of $1,624,000.00. Following the completion of the sale, the director directly owned 50,000 shares in the company, valued at $1,624,000. This trade represents a 50.00% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 150,000 shares of company stock valued at $4,853,921. Company insiders own 16.49% of the company’s stock.

Trending Headlines about Eton Pharmaceuticals

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $65 price target, implying meaningful upside from recent trading levels. The analyst projects improving EPS through 2027, reaching $0.26 in Q1, $0.30 in Q2, $0.36 in Q3 and $0.35 in Q4 2027.
• Neutral Sentiment: Reported short interest was listed at zero shares as of August 11, unchanged from the prior period, with a zero-day short-interest ratio. Because the data appears incomplete or anomalous, it provides little useful signal about investor positioning.
• Negative Sentiment: HC Wainwright reduced its EPS forecasts for Q2 2026 to $0.11 from $0.15, Q3 2026 to $0.17 from $0.23, Q4 2026 to $0.19 from $0.25, and full-year 2026 to $0.52 from $0.68. These cuts suggest a slower earnings ramp and are likely the main factor weighing on ETON.
• Negative Sentiment: The revised FY2026 estimate of $0.52 is also below the broader current-year consensus estimate of $0.75 per share, increasing concern that near-term results may fall short of expectations.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.